The Solution: Bastet 101

Multiple Failures

NASH drug development has had multiple failures due to lack of efficacy and/or adverse events

• Therapies for NASH have seen multiple failures due to lack of efficacy and/or adverse events with these (current) therapies

Bastet 101

• Mechanisms of action target the broad etiology of NASH
  
• Liver-specific targeting enhances the safety profile

Patient Need

Targeting an unmet need in an area of high decompensated liver patient mortality

• More likely acceptance by the medical and payor community
  

Several pathways are implicated to play a role in NASH pathophysiology from the progression of normal liver fat levels to steatohepatitis and, consequently, fibrosis of the liver. However, the emergence of KOLs and payers noting that higher costs of treatment will disrupt reimbursement rates but will also result in potentially higher efficacy results and an increased likelihood of administration.